Dr. Hsieh received his Ph.D. at the Johns Hopkins University and before joining the MSKCC he held faculty positions at Harvard Medical School and Washington University School of Medicine. With Dr. Motzer, they founded the MSKCC translational kidney cancer research program (TKCRP). After its inception in the early 2011, TKCRP has rapidly expanded its research agenda to include generation of new kidney cancer cell lines, establish human in mouse kidney cancer models, develop novel treatment strategy, and initiate cell death mechanism-based clinical trials. Their mission is to decode molecular bases underlying treatment response and cancer metastasis, and develop personalized treatment regimens for kidney cancer patients.